Generic Sterile Injectable Ecosystem Market By Drug Type (Antibiotics, Blood Clotting Factors, Cytokines, Immunoglobulin, Insulin, Monoclonal Antibodies, Peptide Hormones, Vaccines, Others), By Therapeutic Application (Cancer, Cardiovascular Disease (CVD), Central Nervous System, Diabetes, Musculoskeletal System, Others), By Distribution Channel (Drug Stores, Hospitals, Retail Pharmacies): Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2026

Published Date: 06-Jan-2021 Category: Medical Device Report Format : PDF Pages: 110 Report Code: ZMR-5626 Status : Published

The generic sterile injectable ecosystem market is set for a rapid growth over the forecast period. In terms of revenue, the global generic sterile injectable ecosystem market accounted for USD 68.94 Billion in 2019 and is expected to reach USD 149.70 Billion by 2026, growing at a CAGR of 11.71%.

Description

The generic sterile injectable ecosystem market is set for a rapid growth over the forecast period. In terms of revenue, the global generic sterile injectable ecosystem market accounted for USD 68.94 Billion in 2019 and is expected to reach USD 149.70 Billion by 2026, growing at a CAGR of 11.71%.

Global Generic Sterile Injectable Ecosystem Market: Overview

The generic sterile injectable refers to the biologics used in the treatment of a variety of medications which includes the same active ingredients that are present in the branded versions. Its inactive contents can, however, differ from one another. The generic sterile injectable production method is governed by the U.S. Administration of Food and Administration (FDA) and is the same as its marketed counterparts. According to the U.S. National Center for Health Statistics, when the illness lasts for more than three months within the patient it is considered as chronic disease. Such diseases are marked as one of the major causes of death as they cannot be easily cured by vaccines and other medications.

In 2015, non-communicable chronic diseases accounted for over 38 million deaths worldwide, according to the World Health Organization (WHO). Diabetes, arthritis, asthma, cancer, cardiovascular diseases, and even viral disorders such as Hepatitis or HIV/AIDS are among these diseases. In addition, according to the 2013 factsheet of the Centers for Disease Control and Prevention (CDC), arthritis was the most common cause of disability with 22 million patients diagnosed in the U.S. Due to arthritis, these patients faced obstruction in physical activity. It is also studied that nearly 47 percent of the U.S. population have at least a significant risk factor for cardiovascular disease, majorly due to smoking habits, high blood pressure, and uncontrolled low-density lipoproteins cholesterol. Increasing number of these diseases are anticipated to drive the market growth.

Global Generic Sterile Injectable Ecosystem Market: Growth Factors

Growing number of chronic diseases especially cancer across the globe is predicted to boost the demand for generic sterile injectable ecosystem market over the forecast period. Moreover, the growth of the target market is also being propelled by a rising number of drug manufacturers focused on the development of cancer drugs. In addition, rapid FDA approvals of sterile injectable drugs in combination with shortened approval times for new drug production in cancer cure are increasing the availability of dive drugs and eventually fueling demand in the global market for generic sterile injectables.

The demand is expected to be powered by a variety of favorable factors over the next couple of years. Because of the sedentary lifestyles, aging population, and unhealthy eating habits, cases of chronic diseases have been increasing. This has contributed to a greater demand for generic sterile injectables ecosystem. Furthermore, the country's drug shortages coupled with swift U.S. FDA approvals are expected to improve the production of these medicines. The patent expiry of a large number of marketed injectable drugs is also estimated to help the growth of the industry.

Global Generic Sterile Injectable Ecosystem Market: Segmentation

The global Generic Sterile Injectable Ecosystem market can be segmented into drug type, therapeutic application, distribution channel and region. The drug type is segmented into Antibiotics, Blood Clotting Factors, Cytokines, Immunoglobulin, Insulin, Monoclonal Antibodies, Peptide Hormones, Vaccines, Others. The therapeutic application covers cancer, Cardiovascular Disease (CVD), central nervous system, diabetes, musculoskeletal system and others. Rising number of cancer patient worldwide is projected to increase the demand for generic sterile injectable ecosystem over the forecast period. An increasing number of drug manufacturers focusing on the production of drugs to treat cancer is also expected to drive the cancer segment. CVD and diabetes module are expected to grow at a significant rate, owing to the growth in sedentary lifestyle and availability of unhealthy or junk food in the market. By distribution channel, the market is categorized into drug stores, hospitals, retail pharmacies. Hospital segment is expected to hold a largest share in 2021 because of the growing admission rates of cardiovascular patients due to the impact of COVID-19 in the hospitals.

Global Generic Sterile Injectable Ecosystem Market: Regional Analysis

Based on regions, the global Generic Sterile Injectable Ecosystem market can be divided into five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America and Europe, being developed economies with higher concentration of market players and healthcare resources, are estimated to drive the growth of the global generic sterile injectable market over the forecast period. The rising investment in research and development and advanced used of oncology-based drugs in clinics and hospitals for the treatment of different types of cancers has contributed to the growth of market in North America. Asia Pacific is predicted to grow at a fastest rate between 2019 to 2026, as a majority of manufacturers of low-cost generic injectables are concentrating on establishing healthcare facilities in the region.

Global Generic Sterile Injectable Ecosystem Market: Competitive Players

Some of key players in Generic Sterile Injectable Ecosystem market are Aspen Pharmacare Holding, Ltd., AuroMedics Pharma LLC, Cipla Pharmaceuticals, Inc., CSC Pharmaceuticals, Inc., Fresenius Kabi, Kay Pharma, Lupin Limited, Reddys Laboratories Limited, Sun Pharmaceutical Industries, Ltd., and Valeant Pharmaceuticals, Inc. among others.

Global Generic Sterile Injectable Ecosystem Market: Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1.Preface
    • 1.1.Report Description
    • 1.2.Report Scope
  • Chapter 2.Research Methodulogy
    • 2.1.Research Methodulogy
    • 2.2.Secondary Research
    • 2.3.Primary Research
    • 2.4.Models
      • 2.4.1.Company Share Analysis Model
      • 2.4.2.Revenue Based Modeling
    • 2.5.Research Limitations
  • Chapter 3.Executive Summary
    • 3.1.Global Generic Sterile Injectable Ecosystem Market, 2016 – 2026 (USD Billion)
    • 3.2.Global Generic Sterile Injectable Ecosystem Market: Snapshot
  • Chapter 4.Generic Sterile Injectable Ecosystem Market – Industry Analysis
    • 4.1.Introduction
    • 4.2.Market Drivers
    • 4.3.Market Restraints
    • 4.4.Market Opportunities
    • 4.5.Porter’s Five Forces Analysis
    • 4.6.COVID 19 Impact Analysis
  • Chapter 5.Investment Proposition Analysis
    • 5.1.Global Generic Sterile Injectable Ecosystem Market Attractiveness, By Drug Type
    • 5.2.Global Generic Sterile Injectable Ecosystem Market Attractiveness, By Therapeutic Application
    • 5.3.Global Generic Sterile Injectable Ecosystem Market Attractiveness, By Distribution Channel
    • 5.4.Global Generic Sterile Injectable Ecosystem Market Attractiveness, By Region
  • Chapter 6.Competitive Landscape
    • 6.1.Company Market Share Analysis - 2019
      • 6.1.1.Global Generic Sterile Injectable Ecosystem Market: Company Market Share, 2019
    • 6.2.Strategic Developments
  • Chapter 7.Generic Sterile Injectable Ecosystem Market – Drug Type Segment Analysis
    • 7.1.Global Generic Sterile Injectable Ecosystem Market Overview: by Drug Type
      • 7.1.1.Global Generic Sterile Injectable Ecosystem Market Revenue Share, by Drug Type, 2019 & 2026
    • 7.2.Global Generic Sterile Injectable Ecosystem Market Analysis/Overview – By Drug Type
      • 7.2.1.Antibiotics – Overview/Analysis
      • 7.2.2.Blood Clotting Factors – Overview/Analysis
      • 7.2.3.Cytokines– Overview/Analysis
      • 7.2.4.Immunoglobulin– Overview/Analysis
      • 7.2.5.Insulin– Overview/Analysis
      • 7.2.6.Monoclonal Antibodies– Overview/Analysis
      • 7.2.7.Peptide Hormones– Overview/Analysis
      • 7.2.8.Vaccines– Overview/Analysis
      • 7.2.9.Others– Overview/Analysis
    • 7.3.Antibiotics
      • 7.3.1.Global Generic Sterile Injectable Ecosystem Market for Antibiotics, Revenue (USD Billion) 2016 - 2026
    • 7.4.Blood Clotting Factors
      • 7.4.1.Global Generic Sterile Injectable Ecosystem Market for Blood Clotting Factors, Revenue (USD Billion) 2016 – 2026
    • 7.5.Cytokines
      • 7.5.1.Global Generic Sterile Injectable Ecosystem Market for Cytokines, Revenue (USD Billion) 2016 – 2026
    • 7.6.Immunoglobulin
      • 7.6.1.Global Generic Sterile Injectable Ecosystem Market for Immunoglobulin, Revenue (USD Billion) 2016 – 2026
    • 7.7.Insulin
      • 7.7.1.Global Generic Sterile Injectable Ecosystem Market for Insulin, Revenue (USD Billion) 2016 – 2026
    • 7.8.Monoclonal Antibodies
      • 7.8.1.Global Generic Sterile Injectable Ecosystem Market for Monoclonal Antibodies, Revenue (USD Billion) 2016 – 2026
    • 7.9.Peptide Hormones
      • 7.9.1.Global Generic Sterile Injectable Ecosystem Market for Peptide Hormones, Revenue (USD Billion) 2016 – 2026
    • 7.1.Vaccines
      • 7.10.1.Global Generic Sterile Injectable Ecosystem Market for Vaccines, Revenue (USD Billion) 2016 – 2026
    • 7.11.Others
      • 7.11.1.Global Generic Sterile Injectable Ecosystem Market for Others, Revenue (USD Billion) 2016 – 2026
  • Chapter 8.Generic Sterile Injectable Ecosystem Market – Therapeutic Application Segment Analysis
    • 8.1.Global Generic Sterile Injectable Ecosystem Market Overview: by Therapeutic Application
      • 8.1.1.Global Generic Sterile Injectable Ecosystem Market Revenue Share, by Therapeutic Application, 2019 & 2026
    • 8.2.Global Generic Sterile Injectable Ecosystem Market Analysis/Overview – By Therapeutic Application
      • 8.2.1.Cancer – Overview/Analysis
      • 8.2.2.Cardiovascular Disease – Overview/Analysis
      • 8.2.3.Central Nervous System – Overview/Analysis
      • 8.2.4.Diabetes – Overview/Analysis
      • 8.2.5.Musculoskeletal System– Overview/Analysis
      • 8.2.6.Others– Overview/Analysis
    • 8.3.Cancer
      • 8.3.1.Global Generic Sterile Injectable Ecosystem Market for Cancer, Revenue (USD Billion) 2016 - 2026
    • 8.4.Cardiovascular Disease
      • 8.4.1.Global Generic Sterile Injectable Ecosystem Market for Cardiovascular Disease, Revenue (USD Billion) 2016 - 2026
    • 8.5.Central Nervous System
      • 8.5.1.Global Generic Sterile Injectable Ecosystem Market for Central Nervous System, Revenue (USD Billion) 2016 - 2026
    • 8.6.Diabetes
      • 8.6.1.Global Generic Sterile Injectable Ecosystem Market for Diabetes, Revenue (USD Billion) 2016 - 2026
    • 8.7.Musculoskeletal System
      • 8.7.1.Global Generic Sterile Injectable Ecosystem Market for Musculoskeletal System, Revenue (USD Billion) 2016 - 2026
    • 8.8.Others
      • 8.8.1.Global Generic Sterile Injectable Ecosystem Market for Others, Revenue (USD Billion) 2016 - 2026
  • Chapter 9.Generic Sterile Injectable Ecosystem Market – Distribution Channel Segment Analysis
    • 9.1.Global Generic Sterile Injectable Ecosystem Market Overview: by Distribution Channel
      • 9.1.1.Global Generic Sterile Injectable Ecosystem Market Revenue Share, by Distribution Channel, 2019 & 2026
    • 9.2.Global Generic Sterile Injectable Ecosystem Market Analysis/Overview – By Distribution Channel
      • 9.2.1.Drug Stores – Overview/Analysis
      • 9.2.2.Hospitals – Overview/Analysis
    • 9.3.Drug Stores
      • 9.3.1.Global Generic Sterile Injectable Ecosystem Market for Drug Stores, Revenue (USD Billion) 2016 - 2026
    • 9.4.Hospitals
      • 9.4.1.Global Generic Sterile Injectable Ecosystem Market for Hospitals, Revenue (USD Billion) 2016 - 2026
    • 9.4.Retail Pharmacies
      • 9.4.1.Global Generic Sterile Injectable Ecosystem Market for Retail Pharmacies, Revenue (USD Billion) 2016 - 2026
  • Chapter 10.Generic Sterile Injectable Ecosystem Market – Regional Analysis
    • 10.1.Global Generic Sterile Injectable Ecosystem Market: Regional Overview
      • 10.1.1.Global Generic Sterile Injectable Ecosystem Market Revenue Share, by Region, 2019 & 2026
      • 10.1.2.Global Generic Sterile Injectable Ecosystem Market Revenue, by Region, 2016 – 2026 (USD Billion)
    • 10.2.North America
      • 10.2.1.North America Generic Sterile Injectable Ecosystem Market Revenue, 2016 - 2026 (USD Billion)
      • 10.2.2.North America Generic Sterile Injectable Ecosystem Market Revenue, by Country, 2016 – 2026 (USD Billion)
      • 10.2.3.North America Generic Sterile Injectable Ecosystem Market Revenue, by Drug Type, 2016 – 2026
      • 10.2.4.North America Generic Sterile Injectable Ecosystem Market Revenue, by Therapeutic Application, 2016 – 2026
      • 10.2.5.North America Generic Sterile Injectable Ecosystem Market Revenue, by Distribution Channel, 2016 – 2026
      • 10.2.6. U.S.
      • 10.2.7.Canada
    • 10.3.Europe
      • 10.3.1.Europe Generic Sterile Injectable Ecosystem Market Revenue, 2016 - 2026 (USD Billion)
      • 10.3.2.Europe Generic Sterile Injectable Ecosystem Market Revenue, by Country, 2016 – 2026 (USD Billion)
      • 10.3.3.Europe Generic Sterile Injectable Ecosystem Market Revenue, by Drug Type, 2016 – 2026
      • 10.3.4.Europe Generic Sterile Injectable Ecosystem Market Revenue, by Therapeutic Application, 2016 – 2026
      • 10.3.5.Europe Generic Sterile Injectable Ecosystem Market Revenue, by Distribution Channel, 2016 – 2026
      • 10.3.6.Germany
      • 10.3.7.France
      • 10.3.8. U.K.
      • 10.3.9.Rest of Europe
    • 10.4.Asia Pacific
      • 10.4.1.Asia Pacific Generic Sterile Injectable Ecosystem Market Revenue, 2016 - 2026 (USD Billion)
      • 10.4.2.Asia Pacific Generic Sterile Injectable Ecosystem Market Revenue, by Country, 2016 – 2026 (USD Billion)
      • 10.4.3.Asia Pacific Generic Sterile Injectable Ecosystem Market Revenue, by Drug Type, 2016 – 2026
      • 10.4.4.Asia Pacific Generic Sterile Injectable Ecosystem Market Revenue, by Therapeutic Application, 2016 – 2026
      • 10.4.5.Asia Pacific Generic Sterile Injectable Ecosystem Market Revenue, by Distribution Channel, 2016 – 2026
      • 10.4.6.China
      • 10.4.7.Japan
      • 10.4.8.India
      • 10.4.9.Rest of Asia Pacific
    • 10.5.Latin America
      • 10.5.1.Latin America Generic Sterile Injectable Ecosystem Market Revenue, 2016 - 2026 (USD Billion)
      • 10.5.2.Latin America Generic Sterile Injectable Ecosystem Market Revenue, by Country, 2016 – 2026 (USD Billion)
      • 10.5.3.Latin America Generic Sterile Injectable Ecosystem Market Revenue, by Drug Type, 2016 – 2026
      • 10.5.4.Latin America Generic Sterile Injectable Ecosystem Market Revenue, by Therapeutic Application, 2016 – 2026
      • 10.5.5.Latin America Generic Sterile Injectable Ecosystem Market Revenue, by Distribution Channel, 2016 – 2026
      • 10.5.6.Brazil
      • 10.5.7.Mexico
      • 10.5.8.Rest of Latin America
    • 10.6.The Middle-East and Africa
      • 10.6.1.The Middle-East and Africa Generic Sterile Injectable Ecosystem Market Revenue, 2016 - 2026 (USD Billion)
      • 10.6.2.The Middle-East and Africa Generic Sterile Injectable Ecosystem Market Revenue, by Country, 2016 – 2026 (USD Billion)
      • 10.6.3.The Middle-East and Africa Generic Sterile Injectable Ecosystem Market Revenue, by Drug Type, 2016 – 2026
      • 10.6.4.The Middle-East and Africa Generic Sterile Injectable Ecosystem Market Revenue, by Therapeutic Application, 2016 – 2026
      • 10.6.5.The Middle-East and Africa Generic Sterile Injectable Ecosystem Market Revenue, by Distribution Channel, 2016 – 2026
  • Chapter 11.Company Profiles
    • 11.1.Aspen Pharmacare Hulding, Ltd.
    • 11.2.AuroMedics Pharma LLC
    • 11.3.Cipla Pharmaceuticals, Inc.
    • 11.4.CSC Pharmaceuticals, Inc.
    • 11.5.Fresenius Kabi
    • 11.6.Kay Pharma
    • 11.7.Lupin Limited
    • 11.8.Reddys Laboratories Limited
    • 11.9.Sun Pharmaceutical Industries, Ltd.
    • 11.1.Valeant Pharmaceuticals, Inc.

Methodology


Frequently Asked Questions

Growing number of chronic diseases especially cancer across the globe is predicted to boost the demand for generic sterile injectable ecosystem market over the forecast period. Moreover, the growth of the target market is also being propelled by a rising number of drug manufacturers focused on the development of cancer drugs. The demand is expected to be powered by a variety of favorable factors over the next couple of years. Because of the sedentary lifestyles, aging population, and unhealthy eating habits, cases of chronic diseases have been increasing. This has contributed to a greater demand for generic sterile injectables ecosystem.

According to Zion Market Research, the Generic Sterile Injectable Ecosystem market is expected to generate revenue of around USD 68.94 Billion in 2019 and is expected to reach USD 149.70 Billion by 2026, growing at a CAGR of 11.71%.

North America and Europe, being developed economies with higher concentration of market players and healthcare resources, are estimated to drive the growth of the global generic sterile injectable market over the forecast period. The rising investment in research and development and advanced used of oncology-based drugs in clinics and hospitals for the treatment of different types of cancers has contributed to the growth of market in North America. Asia Pacific is predicted to grow at a fastest rate between 2019 to 2026, as a majority of manufacturers of low-cost generic injectables are concentrating on establishing healthcare facilities in the region.

Some of key players in Generic Sterile Injectable Ecosystem market are Aspen Pharmacare Holding, Ltd., AuroMedics Pharma LLC, Cipla Pharmaceuticals, Inc., CSC Pharmaceuticals, Inc., Fresenius Kabi, Kay Pharma, Lupin Limited, Reddys Laboratories Limited, Sun Pharmaceutical Industries, Ltd., and Valeant Pharmaceuticals, Inc. among others.

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Accept

We have secured system to process your transaction.


We Are On Social